Cortagen Peptid 99%

Cortagen Peptid 99% is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Pro. The peptide was synthesized based on amino acid analysis of cortexin, a polypeptide preparation derived from the cerebral cortex that possesses neurotrophic activity. Cortagen represents a simplified, targeted version of the active components found in that natural brain extract.Unlike longer peptides that must bind to cell surface receptors to produce effects, cortagen is small enough to penetrate cell membranes directly. It can enter the nucleus and interact with DNA to influence gene expression. This makes cortagen fundamentally different from compounds like Semax or Selank that work through neurotransmitter modulation.

Shaanxi Medibridge provides Cortagen Peptid 99% for advanced research applications. Custom labeling and formulation options are available upon request. Choose Shaanxi Medibridge for trusted quality, responsive support, and dependable results in neuroprotection and neuroplasticity research.

Most peptides cannot easily cross cell membranes. Larger peptides like IGF-1 or insulin must bind to receptors on cell surfaces to exert their effects. The signal is then transmitted inside the cell through secondary messenger systems.

Cortagen bypasses this limitation entirely.Its compact four-amino-acid structure allows it to pass through both the cell membrane and the nuclear membrane. This grants cortagen direct access to the DNA within the cell nucleus. Once inside, cortagen can interact with specific DNA sequences to influence which genes are activated or suppressed.

This direct nuclear access makes bioregulators uniquely powerful. Rather than sending signals from outside the cell, they work at the source of protein production itself.

Cortagen modulates gene expression across multiple functional pathways, significantly affecting 110 genes among more than 15,000 studied. It can both increase and decrease gene activity, with distinct effects compared with Vilon, Epithalon, and melatonin. Cortagen also appears to activate ribosomal genes and promote chromatin decondensation, helping release age-repressed genes in a tissue-specific regulatory pattern.

Cortagen acts as an epigenetic regulator, influencing gene expression without changing the DNA sequence itself. It may reactivate age-silenced genes, suppress dysfunction-related genes, and promote heterochromatin decondensation. By restoring access to ribosomal and previously repressed genes, Cortagen supports core synthetic activity and cellular reprogramming, helping explain why its biological effects may persist beyond its physical presence.

Each organ in the body has characteristic peptide sequences involved in local regulatory functions. Bioregulators are designed to match these sequences, which is why they show organ-specific effects.

Cortagen was derived from cerebral cortex tissue and contains sequences recognized by neural cells. When cortagen enters the body, it is recognized by brain and nervous system tissue because it matches peptide sequences that these cells use for internal communication. This recognition causes the peptide to concentrate its effects in neural tissue rather than being distributed randomly throughout the body.

A rat study published in the Bulletin of Experimental Biology and Medicine evaluated Cortagen after sciatic nerve transection and repair. Animals received intramuscular Cortagen at 10 mcg/kg daily for 10 days, while controls received saline. After five months, Cortagen-treated rats showed markedly improved nerve recovery, including a 27% increase in regenerating fiber growth rate and a 40% improvement in conduction velocity, especially in sensory and motor myelinated A-fibers.

The research team concluded that cortagen elicits potent neurotrophic activity and promotes both functional and structural recovery of damaged afferent nerves. Researchers also noted that cortagen administration resulted in a decrease in neuroma formation at the suture site, suggesting improved quality of nerve healing.

A study published in The Open Neuropsychopharmacology Journal examined the psychoactive effects of cortagen in mice using elevated plus maze and locomotor activity habituation paradigms. Mice were injected with cortagen at doses of 0.01, 0.03, or 0.10 mg/kg and tested for both acute and sub-chronic responses.

The results revealed an interesting dose-dependent pattern. The 0.03 mg/kg dose of cortagen enhanced locomotion both upon acute and after sub-chronic treatment while having minimal effects on anxiety-related behavior.

The peptide enhances synaptic plasticity by modulating neurotransmitter activity, including the regulation of glutamate and GABA, which supports balanced neuronal signaling. This is fundamentally different from how compounds like Semax work, which primarily modulate BDNF and melanocortin pathways.

Cortagen also demonstrates influence on neuronal metabolism and antioxidant defenses within the central nervous system. Research suggests it can penetrate the blood-brain barrier and directly influence protein synthesis within neurons and glial cells.